Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
about
Fine-tuning multiprotein complexes using small moleculesTen things you should know about protein kinases: IUPHAR Review 14Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsCrystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase InhibitionStructure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold MorphingIdentification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structuresDockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations.Measuring and interpreting the selectivity of protein kinase inhibitorsTinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.Checkpoint kinase inhibitors: a patent review (2009 - 2010).Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors.Harnessing allostery: a novel approach to drug discovery.The hunt for antimitotic agents: an overview of structure-based design strategies.Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compoundsNovel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.Kinase-targeted cancer therapies: progress, challenges and future directions.Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.Integrated one-flow synthesis of heterocyclic thioquinazolinones through serial microreactions with two organolithium intermediates.Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors.
P2860
Q26822675-FC7319DB-F1EA-4273-BAC1-9513A41F043FQ26849417-80BE7687-DEC4-4150-93CD-8B311058F141Q26864870-8F9E5174-0593-4FC9-A04D-C5D573A23F97Q27658951-91BAC754-1783-49DD-B047-F4742E67CFF3Q27664839-43C2F22A-23A2-4C92-A829-C8F58467B48FQ27675773-851B42F0-F790-4D2A-B537-C1092F498E01Q35329233-DC83F7C4-F342-4E02-9CEA-FF3DBD56509BQ35630615-4E0E2AD9-ACF2-40EE-B313-C28E724A54FFQ35649682-505094C6-6732-4681-B41F-9A0E3E0E00AEQ37537075-98B3F289-35F1-4EEA-A2C5-402FF1E4B561Q37856294-8CDFDB87-E06B-4584-9F60-B174ED4ACB7DQ37877694-94B8A80F-7919-45B4-A527-7B354A4DD68FQ37992086-3CC2CF41-4F6B-40E9-B0B0-1A1F8926EAE2Q38028535-FBB3284F-B4C7-4FB4-9730-84D5F61E90C6Q38211688-9D3ECC7D-2264-4903-B5AD-86300B772110Q38808120-AB084D6F-93A8-4B62-BCD4-986B2AE259FDQ38830991-8FC485FF-B667-48CB-BE0B-ACA261F4A9DBQ39226865-E2C0B7E5-08F7-4D8A-A9A8-B7BA19CC5FB7Q49887882-55872371-E525-4441-BFF1-0CBA0503A46BQ53397319-BEB3EC4D-492C-46A2-B50C-47022FE51158Q53658439-DE710BDE-2D25-443E-8F32-57BB3B43F226Q54346146-91EDC051-A956-4A0A-8801-449D7AD8B337
P2860
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@ast
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@en
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@nl
type
label
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@ast
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@en
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@nl
prefLabel
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@ast
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@en
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@nl
P2093
P1476
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
@en
P2093
Antonella Converso
Bob Drakas
Carolyn A Buser
Constantine Kreatsoulas
Edward Tasber
Eileen S Walsh
George D Hartman
Joan Zugay-Murphy
Keith Rickert
Kelly Hamilton
P304
P356
10.1016/J.BMCL.2008.12.076
P407
P577
2009-02-15T00:00:00Z